Unexpected Evaluation of Coronary Heart Disease Medical Outcomes and Clinical Translation PEACE Study Results May 11, 2005

Unexpected Evaluation of Coronary Heart Disease Medical Outcomes and Clinical Translation (PEACE) Study Results May 11, 2005

In recent years, the introduction of ACE inhibitors has brought well-known benefits to patients with coronary artery disease. However, evidence-based research conducted by multiple authoritative institutions in the United States, including Harvard University, University of Washington, and the American Heart Association, using multi-center, large-sample, randomized, double-blind, controlled trial designs, has shown that ACE inhibitors (such as enalapril) do not provide additional benefits for low-risk coronary heart disease patients. Experts were surprised by these findings! The explanation given is: ① Most subjects had previously received statin therapy, resulting in relatively low LDL cholesterol levels. Therefore, for this group of subjects, enalapril no longer offers substantial additional benefits, since ACE inhibitors and statins have broadly similar mechanisms of action. ② Not all ACE inhibitors have the same or equivalent effects. For example, a recent study showed that quinapril is far more effective than enalapril in reducing C-reactive protein levels. A research report from the University of Michigan suggests that many coronary heart disease patients who have not experienced myocardial remodeling, even after receiving interventional or lipid-lowering treatments, do not gain additional cardiovascular protection from ACE inhibitor therapy. This can help reduce unnecessary medication burdens and economic losses for patients.